Local Drug Activation

Shasqi platform for local drug activation.

approach1.png

1. Local gel injection

Shasqi gel is injected at the tumor site. The gel contains activating agents that are inert in the body. These agents enable the concentration and activation of the full power of chemotherapy drugs directly at the tumor site.

approach2.png

2. Pro-Drug Dose

Patient receives a pro-drug of an FDA-approved drug that has been molecularly modified with a TransC™ compound. This moiety inactivates the drug and allows it to be locally concentrated around the gel and tumor.

approach3.png

3. Pro-Drug Activation

The product of the TransC™ compound and gel leads to the release of the active pro-drug at the tumor site. Our preclinical studies show this approach increases efficacy bringing tumors to remission.

Our technology, based on bioorthogonal chemistry, enables the activation of small molecule drugs at the local tissue-level, improving both their efficacy and safety. The method is independent of endogenous cellular or environmental markers and allows the activation of drugs at a specific location for multiple weeks after the initial preimplantation of the gel at the desired site.

 

Chemotherapy

Local chemotherapy activation.


Shasqi Features

  • Highly modular drug delivery platform
  • New approach to validated cancer pathways
  • Compatible with many small molecule therapies
  • Allows concurrent use of multiple therapies

Technology

Shasqi has created a new way to deliver drugs in the body. Our proprietary local drug activation technology allows delivery of more drug to the tumor with fewer side effects.


10-day treatment course with Shasqi’s local activation technology leads to remission of soft tissue sarcoma tumors.

Therapeutic effect of a doxorubicin pro-drug in a mouse xenograft model of soft tissue sarcoma.

Therapeutic effect of a doxorubicin pro-drug in a mouse xenograft model of soft tissue sarcoma.

 

Immune System

Major opportunity for combination therapies


Shasqi Features

  • Tumor remission after a single 10 day course
  • No tumor recurrence after 3 months
  • No weight loss at 3x MTD
  • No myelosuppression at 3x MTD

Protecting Healthy Cells

This drug delivery system focuses the drug in the desired tissue compartment, increasing efficacy and minimizing adverse events. The improved side effect profile can allow concurrent use of multiple cytotoxic drugs. The preservation of the immune function can allow concurrent use of immunotherapies.


Evaluation of weight loss and reticulocyte count (as a surrogate for bone marrow suppression) in a mouse xenograft model of soft tissue sarcoma.

Evaluation of weight loss and reticulocyte count (as a surrogate for bone marrow suppression) in a mouse xenograft model of soft tissue sarcoma.